Caredx, Inc.

Caredx, Inc., headquartered in Brisbane, California, is a for-profit medical technology company that provides proprietary genetic and molecular diagnostic testing services to the Department of Veterans Affairs as a prime contractor across nine regional Veterans Integrated Service Networks, operating exclusively in full-and-open competition with no set-aside designations. The company operates entirely as a prime contractor (100% of awards); it does not subcontract and maintains no subcontractor relationships in its federal footprint.

Caredx's federal capability portfolio centers on transplant rejection surveillance and post-transplant patient monitoring through two core diagnostic product lines: AlloMap gene expression profiling tests and AlloSure kidney and heart diagnostic tests. These services assess organ rejection risk in transplant recipients and enable ongoing immunosuppression monitoring for veteran beneficiaries. Recent representative work includes a $4.8 million delivery order from Veterans Integrated Service Network 16 (April 2025) for lab tests assessing post-transplant organ rejection; a $2.4 million delivery order from VISN 12 (October 2024) for transplant testing kits; and a $1.6 million delivery order from VISN 12 (February 2026) for transplant testing kits. The company also supplies AlloSure in-home patient testing services, reference laboratory testing, and kidney and heart test kits across the VA's regional networks. Caredx holds multiple indefinite-delivery contracts with individual VISNs, including a $4.4 million five-year IDC with VISN 16 (through March 2030), a $3.8 million small-business-set-aside IDC with VISN 12 (through September 2026), a $2.2 million IDC with VISN 9 (through September 2027), and a $724 thousand IDC with VISN 23 (through January 2027) for in-home testing services designated as sole-source.

Customer concentration is heavily weighted to the VA, which accounts for all 62 awards across 11 distinct customer agencies. Within the VA, VISN 12 leads by both volume and dollars: 12 awards worth $13.6 million combined potential value. VISN 16 ranks second by potential value at $10.2 million (4 awards), despite lower award count than VISN 9, which holds 11 awards worth $6.8 million. VISN 21, VISN 23, VISN 19, and six additional VISNs complete the active customer set. The top five VISNs account for 71% of award count and 95% of combined potential value. Outside the VA, Caredx has sporadic activity with the National Institutes of Health, Centers for Disease Control and Prevention, and Navy Bureau of Medicine and Surgery, but these represent minimal dollar share.

Caredx places task orders under five parent IDCs, all within the VA system. The largest vehicle by task-order count and value is Indefinite Delivery Contract 36C25221D0074 (7 task orders, $9.6 million combined potential value), followed by IDC VA25914D0041 (6 task orders, $61 thousand), IDC 36C24922D0027 (5 task orders, $2.2 million), IDC 36C25625D0053 (2 task orders, $5.6 million), and IDC 36C26325D0021 (2 task orders, $312 thousand). All vehicles are single-award or sole-source indefinite-delivery contracts held directly with individual VISNs; no government-wide acquisition contracts, GWACs, or multi-agency vehicles appear in the footprint.

Activity has declined modestly over the past five years, averaging roughly five to seven awards annually with a dip to four awards in 2024. The company faces $5 million in combined potential value across eight awards scheduled for ultimate completion within the next twenty-four months, representing meaningful recompete exposure, particularly within VISN 12 and VISN 16 where contract renewals will determine continued access to those high-value networks. Total federal award portfolio spans 62 prime contracts with $35.7 million in combined potential value and $17 million obligated to date.

Caredx operates three named subsidiaries: Caredx Transplant Management Inc., Caredx Lab Solutions Inc. (a manufacturer of goods), and Immumetrix, Inc. (active in federal grants). The company's service delivery spans multiple locations including Brisbane and Murfreesboro, Tennessee for laboratory and testing operations, and Houston and Iowa City for regional performance sites aligned with VISN footprints. Work classifies predominantly under NAICS 621511 (Medical Laboratories) across 32 awards, with secondary concentrations in testing laboratories and biotechnology research. PSC codes align to reference laboratory testing, laboratory equipment and supplies, and in-vitro diagnostic substances.